|Chemical and physical data|
|Molar mass||318.35 g·mol−1|
|3D model (JSmol)|
Belinostat, sold under the brand name Beleodaq, is a medication used to treat blood cancers and solid tumors. It is used for peripheral T-cell lymphoma. It is given by injection into a vein.: 180
It is a histone deacetylase inhibitor.
Mechanism of action
In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer. Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.
- "Beleodaq (belinostat) For Injection, For Intravenous Administration. Full Prescribing Information" (PDF). Spectrum Pharmaceuticals, Inc. Irvine, CA 92618. Archived from the original (PDF) on 4 March 2016. Retrieved 21 November 2015.
- Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, et al. (August 2003). "Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101". Molecular Cancer Therapeutics. 2 (8): 721–8. PMID 12939461.
- "FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma". FDA. 3 July 2014.
- Bragalone DL, American Pharmacists Association, Lexi-Comp, Inc. (2016). Drug Information Handbook for Oncology (14th ed.). Wolters Kluwer. ISBN 9781591953517.
- Spreitzer H (4 August 2014). "Neue Wirkstoffe – Belinostat". Österreichische Apothekerzeitung (in German) (16/2014): 27.CS1 maint: unrecognized language (link)
- Carroll J (2 February 2010). "Spectrum adds to cancer pipeline with $350M deal". Fierce Biotech.
- "CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference". October 2007. Archived from the original on 2011-07-16. Retrieved 2011-12-06.
- Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma, December 2009